trending Market Intelligence /marketintelligence/en/news-insights/trending/JgDCe-iq3DHdYywAIJq9dg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Horizon's urea disorder drug gets FDA nod for expanded use in newborns

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Horizon's urea disorder drug gets FDA nod for expanded use in newborns

Horizon Pharma PLC's medicine Ravicti was approved by the U.S. Food and Drug Administration to treat infants younger than two months old with a urea cycle disorder.

The Irish biopharmaceutical company said the oral liquid Ravicti, or glycerol phenylbutyrate, is now approved for chronic management of urea cycle disorder, or UCD, in adults and children of all ages whose symptoms cannot be managed by avoiding eating protein or by supplementing with amino acids.

UCD is an inherited disease that makes it hard for a patient's body to remove waste products after digesting proteins. Usually, the nitrogen produced by the breakdown of proteins is converted to a compound called urea and removed from the body, but in UCD the nitrogen accumulates in the form of ammonia. UCD affects about 1 in 35,000 live births in the U.S., said the company.

The company said Ravicti must be used with dietary protein restriction and in some cases with dietary supplements.

Horizon said the approval was based on positive data from a study that showed that children younger than two months who were treated with the drug maintained stable ammonia levels compared to when they had not begun the therapy. Ravicti was also found to be safe in these patients.

Earlier in September, Horizon settled a patent suit against Par Pharmaceutical Inc., which is looking to market a generic version of Ravicti.